Literature DB >> 29644978

Unmet needs and new models for future trials in autoimmune hepatitis.

David Jones1, Michael P Manns2, Luigi Terracciano3, Michael Torbenson4, John M Vierling5.   

Abstract

Despite advances in understanding and treatment of autoimmune hepatitis, important unmet clinical needs remain in both adult and paediatric patient populations. The evolving research landscape and assembly of large patient cohorts are creating unique opportunities to translate science into new therapies and care pathways, with the potential to substantially improve the lives of patients with autoimmune hepatitis. However, these areas of unmet need represent real challenges that need to be addressed if this vision is to be realised. In this Viewpoint, we outline the challenges in adult autoimmune hepatitis, particularly in relation to disease-modifying therapy, and trial design and delivery. Paediatric autoimmune hepatitis presents its own set of challenging problems.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29644978     DOI: 10.1016/S2468-1253(18)30043-8

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  6 in total

Review 1.  Autoimmune Hepatitis Beyond Steroids: Effective Trial Design and Attention to Quality of Life.

Authors:  Christoph Schramm
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-08-02

2.  The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study.

Authors:  David E J Jones; Aaron Wetten; Ben Barron-Millar; Laura Ogle; George Mells; Steven Flack; Richard Sandford; John Kirby; Jeremy Palmer; Sophie Brotherston; Laura Jopson; John Brain; Graham R Smith; Steve Rushton; Rebecca Jones; Simon Rushbrook; Douglas Thorburn; Stephen D Ryder; Gideon Hirschfield; Jessica K Dyson
Journal:  EBioMedicine       Date:  2022-05-21       Impact factor: 11.205

Review 3.  Epigenetic Aspects and Prospects in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

Review 4.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

Review 5.  Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2021-04-09       Impact factor: 3.199

6.  Overlooked Symptoms in Autoimmune Hepatitis Negatively Impact Many Facets of Life.

Authors:  Emma Jones; Margaret Watkins; Erin Anderson; Kayla Gelow; Kelsey Green; Claire Draucker; Craig Lammert
Journal:  Dig Dis Sci       Date:  2022-04-19       Impact factor: 3.487

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.